Sean Laaman
Stock Analyst at Morgan Stanley
(4.63)
# 650
Out of 5,182 analysts
27
Total ratings
72.73%
Success rate
20.04%
Average return
Main Sectors:
Stocks Rated by Sean Laaman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GENB Generate Biomedicines | Initiates: Overweight | $20 | $12.45 | +60.64% | 1 | Mar 24, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Overweight | $32 | $8.74 | +266.13% | 1 | Mar 2, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $96 → $98 | $74.52 | +31.51% | 2 | Feb 25, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $48 → $49 | $44.65 | +9.74% | 6 | Feb 2, 2026 | |
| AXSM Axsome Therapeutics | Downgrades: Equal-Weight | $196 → $204 | $187.40 | +8.86% | 4 | Jan 8, 2026 | |
| CERT Certara | Maintains: Equal-Weight | $16 → $12 | $6.24 | +92.31% | 2 | Dec 18, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Overweight | $20 | $8.79 | +127.53% | 1 | Dec 5, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Overweight | $34 | $30.64 | +10.97% | 1 | Nov 21, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $90 → $115 | $68.85 | +67.03% | 3 | Oct 30, 2025 | |
| RMD ResMed | Maintains: Overweight | $298 → $304 | $222.02 | +36.92% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $383 | $298.90 | +28.14% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $3 → $1.5 | $2.35 | -36.17% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $67 | $64.49 | +3.89% | 1 | Feb 14, 2025 |
Generate Biomedicines
Mar 24, 2026
Initiates: Overweight
Price Target: $20
Current: $12.45
Upside: +60.64%
Eikon Therapeutics
Mar 2, 2026
Initiates: Overweight
Price Target: $32
Current: $8.74
Upside: +266.13%
BridgeBio Pharma
Feb 25, 2026
Maintains: Overweight
Price Target: $96 → $98
Current: $74.52
Upside: +31.51%
Exelixis
Feb 2, 2026
Maintains: Equal-Weight
Price Target: $48 → $49
Current: $44.65
Upside: +9.74%
Axsome Therapeutics
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $196 → $204
Current: $187.40
Upside: +8.86%
Certara
Dec 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $12
Current: $6.24
Upside: +92.31%
BridgeBio Oncology Therapeutics
Dec 5, 2025
Initiates: Overweight
Price Target: $20
Current: $8.79
Upside: +127.53%
MapLight Therapeutics
Nov 21, 2025
Initiates: Overweight
Price Target: $34
Current: $30.64
Upside: +10.97%
Disc Medicine
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $115
Current: $68.85
Upside: +67.03%
ResMed
Oct 21, 2025
Maintains: Overweight
Price Target: $298 → $304
Current: $222.02
Upside: +36.92%
Oct 20, 2025
Maintains: Overweight
Price Target: $350 → $383
Current: $298.90
Upside: +28.14%
Mar 7, 2025
Assumes: Underweight
Price Target: $3 → $1.5
Current: $2.35
Upside: -36.17%
Feb 14, 2025
Assumes: Overweight
Price Target: $67
Current: $64.49
Upside: +3.89%